Post by Kearney

Pharma leaders have the ability to reshape the drug value chain. Public policy changes, reimbursement pressures, PBM market disruption, and the growing impact of GLP-1 therapies are reshaping where value is created and who captures it. In their latest Chain Drug Review article, Kearney’s Todd Huseby, Michael Carr, and Tonny Huang explore how retail pharmacies can navigate this shifting landscape. Explore four potential future scenarios and next steps for building resilience, strengthening partnerships, and unlocking new sources of growth: https://bit.ly/4vzih9J